Skip to main content
Premium Trial:

Request an Annual Quote

ESA to Integrate Waters’ Informatics Platform with HPLC Detector

NEW YORK (GenomeWeb News) – ESA Biosciences said today that it is collaborating with Waters to integrate its Corona CAD universal HPLC detector with Waters’ Empower 2 chromatography control and data analysis platform.
UK-based ESA said that many pharmaceutical scientists already combine a Empower 2 software-controlled LC system with the Corona CAD detector for a variety of applications including excipient and formulation characterization, impurity analysis, cleaning validation, and final product quality control. Jasmine Gruia-Gray, VP of life sciences marketing at ESA, added that the firm’s customers have asked for a direct interface of the two products.
The firms expect to complete the integration project in the third quarter of 2008. ESA said that it would provide the Empower 2 software driver free of charge to existing Corona CAD customers.

Further terms of the alliance were not disclosed.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.